Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for GSK plc (GSK) provides access to the company’s regulatory disclosures as a foreign private issuer. GSK files an annual report on Form 20-F and frequent current reports on Form 6-K under the Securities Exchange Act of 1934. These documents, together with information on American Depositary Shares listed on the New York Stock Exchange, form a key source of official information for investors analyzing GSK stock.
Recent Form 6-K filings include multiple transaction notifications for persons discharging managerial responsibilities (PDMRs) and persons closely associated with them. These reports detail acquisitions of ordinary shares or American Depositary Shares, often through dividend reinvestment plans, share reward plans or the exercise of options under GSK’s share save arrangements, and specify trade dates, prices, volumes and trading venues such as the London Stock Exchange and New York Stock Exchange.
Other 6-K filings report total voting rights, including the number of issued ordinary shares, treasury shares and the resulting total voting rights figure. This information helps shareholders determine whether they must notify changes in their holdings under applicable disclosure rules. Additional 6-K submissions incorporate press releases on significant product approvals, clinical trial results and agreements, such as approvals for Exdensur (depemokimab), Nucala (mepolizumab) in COPD, Shingrix prefilled syringe presentations, and positive phase III results for bepirovirsen in chronic hepatitis B.
On Stock Titan, these filings are complemented by AI-powered summaries that explain the practical meaning of each document. Investors can quickly understand insider dealing reports, changes in capital structure, and major regulatory or clinical events without reading every line of the original filing. Real-time updates from EDGAR ensure that new GSK 6-K submissions, as well as the annual 20-F, appear promptly, while insider transactions analogous to Form 4 in the US domestic context are captured through the PDMR transaction notifications.
By using this page, users can review GSK’s historical and current SEC filings, track patterns in executive and director share dealings, and connect clinical and regulatory announcements to their formal disclosure record, all with the support of AI-generated explanations.
GSK plc reports that on 05 March 2026 it repurchased 650,000 ordinary shares at prices between 2,072.00p and 2,135.00p, with a volume‑weighted average price of 2,102.05p. These shares will be held as treasury shares under its existing buyback programme operated via BNP Paribas.
Since 17 February 2026, GSK has bought back 6,466,000 ordinary shares. After this latest transaction, it holds 246,357,094 shares in treasury and has 4,069,805,394 ordinary shares in issue, which is also the total number of voting rights. Treasury shares now represent 6.05% of voting rights.
GSK plc has published its Annual Report 2025 for the year ended 31 December 2025 on its dedicated website. The report has also been submitted to the UK Financial Conduct Authority’s National Storage Mechanism for public inspection in accordance with UK listing and transparency rules.
Shareholders who have opted for paper communications will receive hard copies of the Annual Report 2025 and the 2026 Annual General Meeting notice on or around 25 March 2026, with the AGM notice made available to all other shareholders on the same date. GSK describes itself as a global biopharma company focused on uniting science, technology, and talent to get ahead of disease.
GSK plc reports that on 04 March 2026 it repurchased 550,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme, at prices between 2,109.00p and 2,149.00p per share and a volume‑weighted average of 2,129.91p.
The shares will be held as treasury shares. Since 17 February 2026, GSK has bought 5,816,000 ordinary shares. After this transaction, it holds 245,707,094 shares in treasury and has 4,070,455,394 ordinary shares in issue, which is also the total number of voting rights. Treasury shares represent 6.04% of voting rights.
GSK plc reported that Chief People Officer Diana Conrad acquired American Depositary Shares under the GSK pension plan. The transaction involved 11.569 ADS at a price of $58.6439 per ADS, executed on 2026-03-02 on the New York Stock Exchange.
GSK plc reports that it bought back 630,000 ordinary shares on 3 March 2026 at a volume‑weighted average price of 2,139.22p, with prices ranging from 2,116.00p to 2,169.00p per share. The shares will be held in treasury as part of its existing share buyback programme executed through BNP Paribas under a non‑discretionary agreement announced on 17 February 2026.
Since that date, GSK has repurchased a total of 5,266,000 ordinary shares. After this latest transaction, it holds 245,157,094 ordinary shares in treasury and has 4,071,005,394 ordinary shares in issue, all carrying voting rights. The percentage of voting rights represented by the treasury shares is confirmed at 6.02%, a figure shareholders can use when assessing disclosure thresholds for holdings.
GSK plc has completed its previously announced acquisition of RAPT Therapeutics, valuing RAPT at an approximate aggregate equity value of $2.2 billion, with GSK’s upfront cash investment around $1.9 billion net of cash acquired.
The deal gives GSK global rights to the food-allergy candidate ozureprubart, excluding mainland China, Macau, Taiwan and Hong Kong. Ozureprubart is a long-acting anti-IgE monoclonal antibody in phase IIb development, aiming for 12‑week dosing versus current 2–4 week injections and potentially serving patients currently ineligible for existing anti‑IgE therapy.
Phase IIb monotherapy data from the prestIgE trial are expected in 2027, with phase III studies planned in at‑risk adult and paediatric populations. GSK will also assume success‑based milestone and royalty obligations for ozureprubart owed to Shanghai Jeyou Pharmaceutical.
GSK plc reports that on 2 March 2026 it repurchased 500,000 ordinary shares of 31¼ pence each through BNP Paribas, at a volume‑weighted average price of 2,180.14p, with prices ranging between 2,168.00p and 2,195.00p per share.
The shares will be held as treasury stock under GSK’s existing buyback programme. Since 17 February 2026, GSK has bought 4,636,000 ordinary shares. After this purchase, it holds 244,527,094 shares in treasury and has 4,071,635,394 voting shares in issue, with treasury shares representing 6.01% of voting rights.
GSK plc reports that, acting through BNP Paribas, it repurchased 430,000 ordinary shares on 27 February 2026 as part of its existing share buyback programme. The shares, with a nominal value of 31¼ pence each, were bought at prices between 2,153.00p and 2,197.00p per share, at a volume‑weighted average price of 2,179.36p.
The purchased shares will be held as treasury shares. Since 17 February 2026, the company has bought back a total of 4,136,000 ordinary shares. Following this latest transaction, GSK holds 244,027,094 shares in treasury and has 4,072,135,394 ordinary shares in issue, which is also the total number of voting rights. Treasury shares now represent 5.99% of voting rights.
GSK plc reports its share capital and voting rights position as of 28 February 2026. The company had 4,316,162,488 issued ordinary shares of 31 ¼ pence each, with 244,027,094 of these held in treasury. Shares held in treasury do not carry voting rights.
After excluding treasury shares, the total number of voting rights in GSK is 4,072,135,394. Shareholders can use this figure as the denominator when calculating whether they must notify the company and the UK regulator of any interests or changes in their holdings.
GSK plc reports that executive Maya Martinez-Davis acquired 70.566 American Depositary Shares at $59.5200 each on 2026-02-20 through dividend reinvestment in her GSK Executive Supplemental Savings Plan account. The transaction took place on the New York Stock Exchange and was disclosed as an initial notification.